Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genzyme licenses TKT's Hunter syndrome candidate

Executive Summary

In a deal that brings two competitors together and settles long-standing litigation between them, Genzyme licensed the rights to develop and sell Transkaryotic Therapies' Phase III enzyme replacement therapy for Hunter syndrome, iduronate-2-sulfatase (I2S), in Japan and other territories within Asia and the Pacific Rim, including Australia and China.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies